VARICELLA DURING PREGNANCY
Varicella-zoster virus (VZV) is spread by respiratory transmission or direct contact with infectious lesions. After primary infection manifest as varicella (chickenpox), VZV becomes latent within sensory ganglia and can cause herpes zoster (shingles) by endogenous reactivation. According to a seroepidemiological study in Germany, the prevalence of VZV-specific IgG class antibodies increases from 7% to 61% after the first to fifth year and reaches 94% among those aged 8 to 9 years.
( 1 ) Only 3.3% of women of child-bearing age in Germany 1 and 9% in the USA 2 are susceptible to primary infection with VZV. The incidence of varicella is calculated as 0.1 to 0.7/1000 pregnancies.
The incubation period from VZV inoculation to onset of varicella usually lasts about 14 (range: 10 to 23) days. In general, the clinical course of chickenpox is mild and self limiting. Persons over 15 years of age and children under 1 year tend to have more severe illnesses with a higher rate of complications. Varicella during pregnancy may occasionally lead to serious maternal and fetal diseases ( Table 1) . Pregnant women who contract varicella in the last trimester are at risk of severe pneumonia and death. The infection can lead to life-threatening ventilatory compromise, and secondary bacterial infections have frequently been observed. Varicella pneumonia has a mortality of 10% to 20% in the general population, but in pregnancy, it may be as high as 45%. More recent studies, however, suggest that the mortality has decreased to 10% to 11% for both nonpregnant and pregnant patients most likely due to the effects of antiviral therapy and better respiratory management. 3 The consequences for the infant depend on the time of infection. At any stage during pregnancy, severe maternal chickenpox may cause intrauterine death. Varicella infection in the first and second trimesters may lead to the congenital varicella syndrome. After infection in the first 20 weeks' gestation, the incidence is estimated to be about 2%. To date, nearly 100 infants born with signs of congenital varicella syndrome have been reported in the literature, more than three quarters of them during the last two decades. 4 The characteristic symptoms consist of skin lesions in dermatomal distribution, neurologic defects, eye diseases, and skeletal anomalies. About 30% of infants born with these lesions died in the first months of life.
Maternal infection near term is associated with a substantial risk of neonatal varicella. Serious disseminated infections with visceral involvement may occur in the affected infants.
NEONATAL VARICELLA
Neonatal varicella can be expected if a mother contracts chickenpox during the last 3 weeks of pregnancy. Maternal chickenpox near term or soon after delivery may cause severe or fatal illness in the newborn. After the disease was first recognized by Hubbard 5 in 1878, hundreds of cases have been reported. 6 -30 Maternal varicella can infect the baby by (1) 
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VZV infection and has a low morbidity rate as most neonates are protected by maternally derived antibodies. 2 However, premature infants younger than 28 weeks' gestation or below 1000 g birth weight are at an increased risk for severe varicella during the first 6 weeks after birth. 31, 32 The severity of intrauterine acquired neonatal chickenpox is closely related to the time of onset of maternal infection as transplacentally transmitted antibodies may reduce the severity of symptoms in the newborn. Generalized neonatal varicella leading to death is much more likely if mothers develop the varicella rash between 4 days before and 2 days after delivery (Table 2) . In several investigations, the maternal rash onset risk period has been extended from 5 days antepartum to 2 days postpartum. 21 After maternal varicella during this period, the risk of severe neonatal chickenpox is generally calculated as 20% to 50% 11, 31, 33 and a fatal outcome has been reported in about 20% of the cases (Table 2 ). These infants have been exposed to maternal viremia without having acquired protecting antibodies. Furthermore, the cell-mediated immune response of the neonate is likely insufficient to retard the hematogenous dissemination of VZV after transplacental spread. 34 A fatal outcome is thus more likely if the neonatal disease occurs between 5 and 10 days after delivery. To our knowledge, 23% of the infants reported in the literature died from a disseminated and fulminant infection ( Table 2 ). Neonatal varicella within the first 4 days after birth has usually been found to be comparatively mild. Fetuses exposed to VZV between 20 and 6 days before delivery may develop neonatal chickenpox, however, with nonfatal course. These infants get maternal antibodies and have therefore a lower risk of complications. As the consequence of neonatal chickenpox, zoster may occur in the infancy, usually with an uncomplicated course. The relatively short viral latency period may be explained by the immature cell-mediated immune response in young children.
Maternal zoster during the perinatal period does not cause problems for newborn infants 20 as the infants possess specific maternal IgG class antibodies and there is no viremic spread of VZV.
Neonatal chickenpox has been occasionally referred to as ''congenital varicella'' or ''neonatal varicella syndrome''. 13, 26, 35 These terms do not allow a clear differentiation from the ''congenital varicella syndrome'' caused by maternal chickenpox in the first two trimesters.
In our own investigations, nine neonates of women with chickenpox from 14 to 0 days before delivery were tested serologically. Seven neonates had positive VZV-specific IgM class antibodies indicating active infection and six of them developed varicella during the first 10 days of life. Three of these neonates diseased at the age of 1 to 4 days. Their mothers had developed chickenpox 5 to 12 days before delivery. The other three neonates had the onset of varicella within 5 to 10 days after birth. In their mothers, the varicella rash was diagnosed between 0 and 3 days before delivery.
One female newborn (Figure 1 ) of the last group delivered at 36 weeks' gestation died from the infection. Two days before delivery, the mother developed the characteristic skin rash of chickenpox. The infant was transferred from the nursery to the isolation ward and received 1.5 ml varicella-zoster immune globulin (VZIG) Zostergam. After 1 week, the girl was discharged home. Because of unclear skin lesions appearing on the face, she was hospitalized again on the 10th day. One day later, the child developed generalized skin rash. The baby died from respiratory distress on the 16th day. Autopsy revealed typical varicella rash on the skin and the mucous membrane of the mouth, confluent hemorrhagic-necrotizing pneumonia, necrotizing hepatitis (Figure 2) , as well as focal necroses of the intestinal mucous membranes, spleen, adrenal glands, and brain. Virological investigations confirmed the diagnosis of varicella by detecting VZV DNA in formalin-fixed liver tissue using polymerase chain reaction and in situ hybridization ( Figure 3) . By electron microscopy, intranuclear herpesvirus-like particles could be seen in specimens from skin lesions as well as in necrotic lesions of liver and lungs.
DIAGNOSIS OF NEONATAL VARICELLA
The diagnosis of neonatal varicella is usually based on the typical clinical picture. In case of intrauterine acquired disease, the characteristic point in time and the maternal history of chickenpox during the last weeks of pregnancy have to be considered. The differential diagnosis includes herpes simplex virus (HSV) and enterovirus infections. A vesicular rash or bullae present at birth or within a few days have been noted in most infants with congenital HSV infections. 26 Intrauterine transmission of coxsackievirus during the late pregnancy may also lead to varicella-like congenital skin lesions. 36 Serological methods have been widely used to confirm the clinical diagnosis of neonatal varicella. Enzyme-linked immunosorbent assay, indirect immunofluorescence, and fluorescent antibody to membrane antigen test have been shown to be reliable for routine diagnosis. However, the detection of virus-specific antibodies is not useful for early diagnosis. In addition, cross-reactions to HSV have to be considered in most antibody assays with VZV-infected cells as antigen, probably based on the known antigenic cross-reactivity of VZV and HSV glycoproteins B. 37 Specific IgG is used as serological proof of immunity to VZV. The detection of IgM/IgA class antibodies is the most convincing evidence for active infection. IgG antibodies should be measured in pregnant women exposed to VZV and with a negative or indeterminate history of varicella. Because of the high rate of seropositive women in child-bearing age, routine antenatal serologic screening is not recommended. Screening could be considered in groups of women with a negative history of varicella and an increased exposure risk to varicella or zoster.
The most sensitive and specific method for the detection of VZV in clinical specimens is the amplification of conserved sequences of viral DNA by polymerase chain reaction. This technique is clearly the method of choice for the investigation of skin swabs or biopsies, liquor specimens, tissue samples, and amniotic fluid for the prenatal diagnosis of fetal infections. 38, 39 Where molecular biologic methods are not available, immunofluorescent VZVspecific antigen staining in vesicle specimens can be recommended. 40 Electron microscopy needs considerable experiences for interpretation and does not differentiate between HSV and VZV. The isolation of VZV in cell culture is not useful for a rapid and sensitive diagnosis of neonatal chickenpox as VZV is extremely labile and cell-associated. The prolonged incubation time for up to several weeks required for cytopathic changes to develop, and the restricted spectrum of human and avian cells susceptible to VZV are obvious disadvantages. However, virus isolation is helpful if molecular characterization of VZV strains or testing for drug sensitivity are required.
PROPHYLAXIS AND TREATMENT OF NEONATAL VARICELLA
Nonimmune pregnant women should be advised to avoid exposure to chickenpox and zoster. VZIG administration should be considered for susceptible pregnant women within 72 to 96 hours of exposure. The recommended dose is 125 U/10 kg of body weight, up to a maximum of 625 U administered intramuscularly 31 or 0.5 ml/kg intramuscularly and 1 ml/kg intravenously, 41 respectively. Although passive immunization of pregnant women may theoretically reduce the risk of fetal infection, there is no evidence that this prevents neonatal varicella. Thus, the primary reason for VZIG is to prevent severe chickenpox and complications in the mother.
VZIG given intramuscularly (dosage: 125 U, 250 mg, or 0.5 ml/kg) or intravenously (dosage: 1 ml/kg) is also indicated for neonates whose mothers have signs and symptoms of varicella between 5 and 7 days before and 2 to 3 days after delivery. 31, 33, 42 Hospitalized premature infants, younger than 28 weeks' gestation or below 1000 g birth weight who are exposed to VZV should receive VZIG, regardless of the maternal history of chickenpox as these infants may not have acquired maternal antibodies. 31 Following treatment, these newborns should be under surveillance in the hospital for 2 weeks, that is, to the end of incubation period. 32, 43 When a neonate who has received VZIG is discharged home, it should be made clear to the parents that prompt hospital review should be undertaken if the baby becomes unwell or develops rash. 28 Passive immunization of the newborn may modify the clinical course of neonatal varicella but it does not prevent the disease and, although decreased, the risk of death is not eliminated. 16, 27, 44 Therefore, acyclovir therapy should be administered promptly at a dosage of 10 to 15 mg/kg every 8 hours intravenously for 5 to 7 days on suspicion of neonatal chickenpox. Prophylactic intravenous acyclovir can prevent neonatal varicella or reduce the severity of the disease markedly.
14, 15 To date, wellcontrolled studies on the use of acyclovir in newborns have not been reported. There are also no experiences with other VZVeffective nucleoside-analogous compounds such as famciclovir or brivudin during the neonatal period.
To reduce the mortality from neonatal chickenpox, the date of delivery may also be postponed allowing maternal antibodies to pass the placental barrier. 23 No therapy is indicated for neonatal chickenpox if the maternal rash onset is more than 7 days before delivery. Mothers and newborns suffering from or being at risk of varicella have to be isolated on maternity wards.
Active immunization with a live-attenuated varicella vaccine (VZV Oka strain) should be offered to nonpregnant women of childbearing age without a history of varicella to provide them protective VZV-specific immunity. 31 The available vaccines proved to be safe and lead to complete protection from severe chickenpox. 45 Pregnancy should be avoided for at least 4 weeks following vaccination. Varicella vaccine, as all live-attenuated vaccines, is contraindicated in pregnant women. Several industrialized countries consider universal immunization of all susceptible children.
